Tilisolol

Drug Profile

Tilisolol

Alternative Names: Daim; N 696; Selecal

Latest Information Update: 14 Jul 2008

Price : $50

At a glance

  • Originator Nisshin Pharma
  • Developer Maruho; Nisshin Pharma; Toyama Chemical
  • Class Antiarrhythmics; Antihypertensives; Ischaemic heart disorder therapies; Isoquinolines
  • Mechanism of Action Beta-adrenergic receptor antagonists; Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Angina pectoris; Hypertension
  • Discontinued Arrhythmias; Glaucoma

Most Recent Events

  • 01 Jul 2008 Toyama Chemical has been acquired by FUJIFILM Holdings Corporation
  • 11 Sep 2000 Discontinued-Preclinical for Glaucoma in Japan (Ophthalmic)
  • 20 May 1997 No-Development-Reported for Glaucoma in Japan (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top